Psychiatry Medical News about Administration, Cutaneous Attention Deficit Disorder with Hyperactivity Methylphenidate

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Omega-3 fatty acids for bipolar disorder

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: A multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials
Clinical Therapeutics, 10/12/09

Findling RL et al. – Slightly less than half (48.0%) of subjects completed this 12–month, open–label extension study of MTS. Most AEs were mild to moderate in severity and, with the exception of application–site reactions, were typical of those previously observed with methylphenidate.

<< Previous
A qualitative study of perceived social barriers to care for...

Next >>
Serum protein profiling and proteomics in autistic spectrum...